Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates

[1]  J. Humm,et al.  PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Steven M. Larson,et al.  Radioimmunotherapy of human tumours , 2015, Nature Reviews Cancer.

[3]  S. Larson,et al.  Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex , 2014, Molecular Cancer Therapeutics.

[4]  J. Andersen,et al.  A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. , 2013, Protein engineering, design & selection : PEDS.

[5]  S. Larson,et al.  Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. , 2013, The New England journal of medicine.

[6]  D. Goldenberg,et al.  Pretargeted Molecular Imaging and Radioimmunotherapy , 2012, Theranostics.

[7]  K Dane Wittrup,et al.  Effect of Small-Molecule–Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody , 2012, Molecular Cancer Therapeutics.

[8]  W. Oyen,et al.  Dosimetric Analysis of 177Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on 111In-cG250 Imaging , 2012, The Journal of Nuclear Medicine.

[9]  K Dane Wittrup,et al.  Practical theoretic guidance for the design of tumor-targeting agents. , 2012, Methods in enzymology.

[10]  J. Humm,et al.  124I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET , 2011, The Journal of Nuclear Medicine.

[11]  J. Humm,et al.  124I-huA33 Antibody PET of Colorectal Cancer , 2011, The Journal of Nuclear Medicine.

[12]  K Dane Wittrup,et al.  Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. , 2011, Nuclear medicine and biology.

[13]  R. Hicks,et al.  ORIGINAL ARTICLE Quantitative 177 Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system , 2011 .

[14]  J. Frangioni,et al.  Biodistribution and Clearance of Small Molecule Hapten Chelates for Pretargeted Radioimmunotherapy , 2011, Molecular Imaging and Biology.

[15]  K Dane Wittrup,et al.  A modular IgG-scFv bispecific antibody topology. , 2010, Protein engineering, design & selection : PEDS.

[16]  E. Yorke,et al.  Use of normal tissue complication probability models in the clinic. , 2010, International journal of radiation oncology, biology, physics.

[17]  Michael M. Schmidt,et al.  A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.

[18]  D. Hnatowich,et al.  A semiempirical model of tumor pretargeting. , 2008, Bioconjugate chemistry.

[19]  Amos A Folarin,et al.  Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas. , 2007, Cancer research.

[20]  D. Scheinberg,et al.  PET Imaging of Soluble Yttrium-86-Labeled Carbon Nanotubes in Mice , 2007, PloS one.

[21]  J. Humm,et al.  Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  C. Meares,et al.  Irreversibly binding anti-metal chelate antibodies: Artificial receptors for pretargeting. , 2006, Journal of inorganic biochemistry.

[23]  Bradley J Beattie,et al.  Quantitative imaging of bromine-76 and yttrium-86 with PET: a method for the removal of spurious activity introduced by cascade gamma rays. , 2003, Medical physics.

[24]  R. Pedley,et al.  Higher Dose and Dose-Rate in Smaller Tumors Result in Improved Tumor Control , 2003, Cancer investigation.

[25]  A. Alavi,et al.  Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. , 2002, Clinical colorectal cancer.

[26]  J. Humm,et al.  Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  C. Meares,et al.  Antibodies with infinite affinity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Humm,et al.  Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  J. Doroshow,et al.  A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Larson,et al.  Quantitative Imaging of Yttrium-86 with PET. The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[31]  J. Humm,et al.  131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  Y. Erdi,et al.  Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 PET Imaging. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[33]  G. Denardo,et al.  New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor. , 1998, Hybridoma.

[34]  F. Real,et al.  Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. , 1996, International journal of oncology.

[35]  J. Humm,et al.  Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM). , 1996, British Journal of Cancer.

[36]  A. Scott,et al.  Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Owens,et al.  Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. , 1995, British Journal of Cancer.

[38]  T. Wheldon,et al.  Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  D. Kukis,et al.  Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy. , 1994, Cancer research.

[40]  A. Scott,et al.  Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  D. Johnson,et al.  Tumor size: effect on monoclonal antibody uptake in tumor models. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  C. Meares,et al.  Antibodies against metal chelates , 1985, Nature.